Proactive Investors - Run By Investors For Investors
Why invest in APH?
Alliance Pharma plc: THE INVESTMENT CASE

Alliance Pharma - a business in rude health

The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
generic pill and bottle shot to denote Alliance's products
Alliance now owns around 90 pharmaceutical and healthcare products and sells into over 100 countries

The latest trading update from Alliance Pharma plc (LON:APH) revealed a company in rude financial health.

It showed Alliance to be a lean, cash generating machine.

It also provided proof, if it were needed, that chief executive John Dawson and his team were right in late 2015 to spend almost £128mln on the healthcare assets of Sinclair Pharma.

This was a deal that has helped catapult Alliance’s market capitalisation from circa £90mln to almost a quarter of a billion pounds.

It also provided the business with a European network.

READ: Alliance's trading update in detail 

A year-and-half on from the transaction’s completion we are seeing in full Technicolor its impact on both the profit and loss account and the balance sheet.

Sales grew 8% in the six months to June 30 to £50.3mln.

Free cash flow was £11.1mln, or around £22mln on an annualised basis, and net debt had fallen by £12.7mln to £63.4mln.

“It demonstrates that the business model we have here, which is asset light - we outsource the capital intensive things like manufacturing and logistics - does really give a high conversion of operating profit into free cash flow,” CEO Dawson says.

Growth by acquisition

The company has grown via a series of well-judged acquisitions (33 in 19 years, reveals Dawson) and Alliance now owns around 90 pharmaceutical and healthcare products and sells into over 100 countries.

In that portfolio it has what it calls ‘local hero’ lines, which sell well in a particular territory or country. The crown jewels are its ‘global stars’, which are managed and marketed centrally and, as the name suggests, are sold internationally.

They are Kelo-Cote, a scar reduction spray and gel, and MacuShield, for an eye condition called age-related macular degeneration.

The former saw its sales increase 52% in the first half to £6.2mln, while the latter’s advanced 67% to £3.4mln. In other words they showed their ‘star’ quality.

There was supposed to be a third international product, Diclectin, for nausea during pregnancy, but it failed to gain UK regulatory sign-off here in the UK.

While a blow to Alliance’s plans, the short-term financial impact will be negligible, analysts say.

Options available

Dawson believes the heavy marketing spend that would have been required to promote the new treatment can be usefully directed elsewhere, although he stresses his team hasn’t decided how the freed-up cash will be invested.

It leaves Alliance looking for a Diclectin replacement, which is likely to come via acquisition or in-licensing rather from within the current portfolio.

With net debt falling towards two-times underlying earnings (EBITDA) by the year-end so the headroom grows for more well-judged purchases.

“Our approach is we will recycle cash generated on bolt-on acquisitions,” says Dawson.

“As well as organic growth we have as another part of the business model growth by bolt-on.”

The shares, which had a little hiccup towards the end of last month when the Diclectin decision was announced, have advanced 15% over the last year. It is also worth pointing out the company pays a tidy dividend that provides a yield of around 2.5%.

An opportunity? 

However, it is probably fair to say the current market valuation fails to fully capture the full potential of the business.

Peer group analysis suggests Alliance Pharma should be valued on an enterprise multiple (EV to EBITDA) of around 13.5 times. It is currently trading two percentage points below that benchmark.

Dawson skilfully skirts tricky questions on valuation, but makes this observation: “I think the challenge is becoming known and established and recognised for success.

“We believe the market is re-adjusting for the better growth prospects we’ve got.”

View full APH profile View Profile

Alliance Pharma plc Timeline

July 31 2017

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
Woman with tissue facing pollen
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use